WallStreetZenWallStreetZen

NASDAQ: FIXX
Homology Medicines Inc Earnings & Revenue

Buy FIXX
OverviewForecastEarnings
DividendOwnership

FIXX past revenue growth

How has FIXX's revenue growth performed historically?
Company
-82.6%
Industry
1,026.85%
Market
157.46%
FIXX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
FIXX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance

FIXX earnings and revenue history

Current Revenue
$5.5M
Current Earnings
-$2.6M
Current Profit Margin
-47.3%

FIXX Return on Equity

Current Company
-1.2%
Current Industry
6.9%
Current Market
38.4%
FIXX's Return on Equity (-1.2%)... subscribe to Premium to read more.
High Return on Equity Performance

FIXX Return on Assets

Current Company
-1%
Current Industry
5.1%
FIXX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

FIXX Return on Capital Employed

Current Company
-0.56%
Current Industry
-16.5%
FIXX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

FIXX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
FIXX$5.47M$6.11M-$2.59M+48.35%N/A
FSTX$20.80M-$32.71M-$33.79M+210.56%N/A
SESN$20.00M$35.40M$47.80M-7.73%+2.59%
PRTG$0.00-$14.77M-$19.17MN/AN/A
ATHA$0.00-$66.40M-$66.97MN/AN/A
View Top Biotech Stocks

Homology Medicines Earnings & Revenue FAQ

What were FIXX's earnings last quarter?

On Invalid Date, Homology Medicines (NASDAQ: FIXX) reported Q1 2022 earnings per share (EPS) of $1.61, up 8,150% year over year. Total Homology Medicines earnings for the quarter were $92.11 million. In the same quarter last year, Homology Medicines's earnings per share (EPS) was -$0.02.

If you're new to stock investing, here's how to buy Homology Medicines stock.

What was FIXX's earnings growth in the past year?

As of Q3 2022, Homology Medicines's earnings has grown year over year. Homology Medicines's earnings in the past year totalled -$2.59 million.

What was FIXX's revenue last quarter?

On Invalid Date, Homology Medicines (NASDAQ: FIXX) reported Q1 2022 revenue of $802.00 thousand up 97.26% year over year. In the same quarter last year, Homology Medicines's revenue was $29.31 million.

What was FIXX's revenue growth in the past year?

As of Q3 2022, Homology Medicines's revenue has grown -82.6% year over year. This is 1,109.45 percentage points lower than the US Biotechnology industry revenue growth rate of 1,026.85%. Homology Medicines's revenue in the past year totalled $5.47 million.
©2022 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending StocksStock Market SectorsStock Market Industries
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.